ArticleEuropean journal of pediatrics2025
Serum golgi protein-73 (GP-73) in children with autoimmune hepatitis.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the correlation between serum Golgi protein-73 (GP-73) and the degree of hepatic fibrosis in children with autoimmune liver diseases. This case-control study included 100 children. Group A involved 50 children with autoimmune hepatitis (AIH), aged 2-17 years (mean 11.3 ± 2.7 years), while Group B included 50 age- and sex-matched healthy controls. All participants underwent clinical assessment, abdominal ultrasonography, laboratory investigations, and measurement of serum GP-73 using enzyme-linked immunosorbent assay. Children with AIH had significantly higher serum GP-73 levels than controls (median 110.7 ng/L vs. 21.3 ng/L, p < 0.001). GP-73 levels showed a strong positive correlation with both the histological activity index (r = 0.879, p < 0.001) and the stage of fibrosis (r = 0.647, p < 0.001). At a cutoff level > 49 ng/L, GP-73 distinguished AIH cases with 100% sensitivity and 100% specificity. For identifying severe fibrosis, a cutoff > 124.6 ng/L yielded 100% sensitivity and 91.7% specificity (area under the ROC curve = 0.995, p < 0.001).
conclusionSerum GP-73 levels are significantly elevated in children with autoimmune hepatitis and correlate strongly with both histological grading and staging. GP-73 may serve as a reliable non-invasive marker for assessing disease severity and guiding clinical management in pediatric autoimmune liver diseases. WHAT IS KNOWN: • Non-invasive biomarkers for assessing liver fibrosis in children with autoimmune hepatitis are still limited, and liver biopsy remains the gold standard despite its risks. WHAT IS NEW: • Serum GP-73 is significantly elevated in pediatric AIH, strongly correlates with fibrosis severity, and may serve as a reliable non-invasive biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.